| SYK |
Report |
Q2 2026 revenue |
BEAT |
pred ~$6.65B vs. cons $6.56B |
MEDIUM |
| SYK |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$3.51 vs. cons $3.46 |
MEDIUM |
| SYK |
Report |
Q2 2026 adjusted operating margin |
IN-LINE |
pred ~25.6% vs. cons 25.4% |
LOW |
| SYK |
Guide |
FY2026 organic sales growth |
UNCHANGED |
guide ~8.75% midpoint vs. cons 8.7% (FY2026) |
HIGH |
| SYK |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide ~$15.00 midpoint vs. cons $14.98 (FY2026) |
MEDIUM |
| SYK |
Guide |
FY2026 adjusted operating-margin expansion |
BETTER |
guide ~50 bps vs. cons 45 bps (FY2026) |
LOW |
| SYK |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.6% |
— |
MEDIUM |
| SYK |
Return |
5-day cumulative residual |
+0.5% (FADE) |
The Q2 beat validates recovery, but an unchanged FY2026 EPS midpoint of ~$15.00 less predicted H1 EPS of ~$6.11 implies H2 EPS of ~$8.89 vs. pre-print consensus of ~$8.92, producing modest out-period estimate cuts and a partial fade. |
MEDIUM |